Last reviewed · How we verify
NCT03744962
MSI in Circulatory DNA of Endometrial Cancer
trial in Microsatellite Instability in 100 participants. Status unknown.
23 December 2020
Quick facts
| Lead sponsor | Lei Li |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 November 2018 |
| Primary completion | 23 December 2020 |
| Estimated completion | 23 December 2020 |
| Sites | 1 location across China |
Conditions studied
- Microsatellite Instability — all drugs for Microsatellite Instability →
- Lynch Syndrome — all drugs for Lynch Syndrome →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Circulating Tumor Cell — all drugs for Circulating Tumor Cell →
Sponsor
Lei Li — full company profile →
Who can join
Eligibility, female only, with Microsatellite Instability or Lynch Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer. These data will be used for the study of "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.
Perez M, Carvajal LL, Wong A, Poppiti R, et al · · 2025 · PMID 40869308 · DOI 10.3390/ijms26167987
Verify or expand the search:
- PubMed search for NCT03744962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Microsatellite Instability
Currently open trials in the same condition.
- NCT04817826 — TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. · Phase 2 · active not recruiting
- NCT03935893 — Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers · Phase 2 · recruiting
- NCT03228667 — QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Check · Phase 2 · active not recruiting
Other Lei Li trials
Trials by the same sponsor.
- NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
- NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
- NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
- NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
- NCT06490380 — HRD Status Reference Standard Based on WGS · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03744962 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lei Li
- Last refreshed: 19 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03744962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing